Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammary

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Dec 2016: Trial registered, NCT02978625
  2. 27 Sep 2017: Trial started, NCT02978625

The trials

NCT02978625: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

State
Under way
Phase
Phase 2
People
68 planned
Started
27 Sep 2017
Primary completion
1 Sep 2027
Arms
Treatment (talimogene laherparepvec, nivolumab)
Results
None posted
  1. 1 Dec 2016: Trial registered
  2. 27 Sep 2017: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.